Gliclada® (30 mg) Gliclazide > Ọgwụgwọ na mgbochi

Mpempe 30 mg agbanwere mbadamba mbugharị

Otu mbadamba ihe

ike - gliclazide 30 mg

ndị na-ebu ụzọ: hypromellose (4000 **), hypromellose (100 **)

carbon dioxide, lactose monohydrate, silikion dioxide, magnesium stearate

** Abamuru nke viscosity aha ya bụ ihe dị mma maka 2% (m / v) ihe nrịba nke hypromellose

Mbadamba ụrọ, site na ọcha ruo ihe na-acha ọcha, biconvex ubé

Ndị na-ere ọgwụ

Pụtara maka ọgwụgwọ maka ọrịa shuga. Ọgwụ shuga dị ala maka nchịkwa ọnụ. Nri nke sulfonylureas. Gliclazide

Koodu ATX A10VB09

Omume ọgwụ

Mlọ ọgwụ

Mgbu na nkesa

Mgbe ị takingụsịrị ọgwụ ahụ n'ime, gliclazide na-abanye kpamkpam na eriri afọ. Nnukwu gliclazide na plasma na-abawanye nwayọ n'oge awa isii mbụ mgbe ọ jesịrị nchịkwa wee rute ala dị larịị nke dị site na 6 ruo awa nke iri na abụọ. Onweghi ike n’otu n’otu di ala. Iri nri anaghị emetụta ogo nke mmịpụta. Olu nkesa kesara odi lita 30. Njikọ protein protein Plasma bụ ihe dịka 95%. Otu ọgwụ kwa ụbọchị nke ọgwụ Gliclada® na-eme ka e nwee ike na - agbakọ uru glyclazide na plasma ọbara ruo ihe karịrị awa 24.

Gliclazide bụ metabolized nke ukwu na imeju. Metabolites ndị a rụpụtara anaghị arụ ọrụ ọgwụ. Mmekọrịta dị n'etiti ọgwụ a were rue 120 mg na ịta ọgwụ na plasma bụ ntinye kwụụrụ n'oge.

Ndụ ndụ ọkara (T1 / 2) nke gliclazide bụ awa 12-20. Ọ na - abụkarị site akụrụ n'ụdị metabolites, ihe na-erughị 1% dị na mmamịrị agbanweghi.

Pharmacokinetics n'ihe gbasara ọrịa

N'ime ndị agadi, enweghị mgbanwe mgbanwe dị egwu a na-achọpụta na ọgwụ ọgwụ.

Mlọ ọgwụ

Gliclada® bụ ọgwụ ọgwụ hypoglycemic nke sitere na otu nke usoro nke sulfonylurea nke ọgbọ nke abụọ, nke dị iche na ọgwụ ndị yiri ya site na ọnụnọ nke heterocyclic nke N-nwere nwere njikọ nke endocyclic.

Glyclada® na-ebelata glucose ọbara site na-akpali insulin na mmiri site n'agwaetiti Langerhans nwere mkpụrụ ndụ R. Mgbe afọ abụọ nke ọgwụgwọ gasịrị, mmụba nke ọkwa insprandial insulin na nzuzo nke C-peptides na-adịgide. Na ụdị ọrịa mellitus nke 2, ọgwụ a na-eweghachi mmalite nke insulin na-emeghachi omume na nzaghachi glucose ma na-eme ka akụkụ nke abụọ nke insulin ahụ dịkwuo elu. A na-ahụta mmụba dị ukwuu na mmiri insulin na nzaghachi mkpali n'ihi nri nri na nchịkwa glucose.

Na mgbakwunye na emetụta metabolism metabolism, Glyclada® nwere mmetụta na microcirculation. Ọgwụ ahụ na-ebelata ihe ize ndụ nke thrombosis nke obere arịa ọbara, na-emetụta usoro abụọ nwere ike itinye aka na mmepe nke nsogbu na ọrịa shuga mellitus: ịhapụ akụkụ nke platelet na nrapado na mbelata ihe ndị na - eme ka platelet (beta-thromboglobulin, thromboxane B2), yana mweghachi nke fibrinolytic vaskụla endothelial ọrụ na ụba ọrụ nke plasminogen anụ ahụ.

Usoro onunu ogwu na nhazi

Emere ọgwụ a naanị maka ndị okenye okenye.

Ọ na-atụ aro iri mbadamba (s) n’etuchaghị nri ụtụtụ. Y’oburu n’icho ozo n’abia ozo, igaghi abawanye ogwu a.

Thebọchị Glyclad® kwa ụbọchị bụ site na 30 ruo 120 mg (mbadamba 1 ruo 4). A na-ahọrọ dose nke ọgwụ ahụ dabere na nzaghachi metabolic nke onye ọrịa.

Usoro akwadoro ịmalite bụ 30 mg kwa ụbọchị. Site na nchịkwa glucose dị irè, enwere ike iji ọgwụ a dịka ọgwụgwọ mmezi.

N'iburu ịchịkwa ọkwa glucose na-ezughị ezu, ị dailyụ ọgwụ kwa ụbọchị nwere ike jiri nwayọ belata 60, 90 ma ọ bụ 120 mg. Oge dị n’etiti ịrị elu nke ọ bụla kwesịrị ịbụ opekata mpe ọnwa 1, ewezuga ndị ọrịa nọ n’ime ọkwa glucose na-ebelataghị ka izu ụka abụọ gachara. N'ọnọdụ ndị dị otú a, enwere ike ịbawanye dose ahụ izu 2 mgbe mmalite ọgwụgwọ. Ogo kachasị akwadoro bụ 120 mg kwa ụbọchị.

Na-agbanwe site na mbadamba 80 Glyclazide na mbadamba mbadamba Glyclad®

N'ihe banyere njikwa ike nke ịba ụba glucose n'ọbara onye ọrịa ya na mbadamba 80 glycoslide, enwere ike dochie ha na Glyclada® na nha 1 mbadamba glycoslide 80 mg = 1 mbadamba nke Glyclada®.

Na-agbanwe site na ọgwụ hypoglycemic ọzọ na Glyclad®

Na ntughari, usoro ogwu na ọkara ndụ nke ọgwụ ịchọrọ aga-atụle. Oge ntụgharị adịghị achọkarị. Nnabata ọgwụ Glyclada® kwesịrị ịmalite na 30 mg, nke na-esote mmezi dabere na mmeghachi omume metabolic.

Mgbe ị na-agbanwe site na ọgwụ ọgwụ ndị ọzọ nke otu sulfonylurea na ndụ ogologo ndụ, iji zere mmụba nke ọgwụ abụọ ahụ, enwere ike ịchọrọ oge ọgwụ na-adịghị ọtụtụ ụbọchị.

N'ụdị ndị a, ntụgharị aka na mbadamba nkume Glyclad® kwesịrị ịmalite site na usoro ọgwụgwọ akwadoro nke 30 mg, nke na-esote mmụba nke ọgwụ na-adabere na mmeghachi omume metabolic.

Jiri ya na ọgwụ ndị ọzọ na-egbochi antidiedi

Enwere ike ịnye gliclada® na njikọ ya na biguanides, alfa-glucosidase inhibitors ma ọ bụ insulin. Ekwesịrị ịmalite ịmalite insulin n'otu oge n'okpuru nlekọta dọkịta.

Ndị okenye (ndị okenye karịrị afọ 65)

Edere ọgwụ ahụ n'otu ọgwụ ahụ maka ndị ọrịa na-erubeghị afọ 65.

N'ime ndị ọrịa nwere ọrụ mkpo ya dị nro ma ọ bụ na-agafeghị oke, a na-edenye ọgwụ ahụ na usoro ọgwụgwọ ọ bụla.

Ndị ọrịa nwere nnukwu ọrịa hypoglycemia: site na nri na-edozi ahụ, na-arịa ọrịa endocrine dị ala ma ọ bụ na-adịghị akwụ ụgwọ (hypopituitarism, hypothyroidism, enweghị adrenocorticotropic homonụ), mgbe ogologo oge na / ma ọ bụ ọgwụ corticosteroid dị elu, ọrịa obi ike, ọgwụgwọ a na-atụ aro ka ịmalite site na opekempe. kwa ụbọchị 30 mg.

Nsonaazụ

hypoglycemia (bụrụ nke ihe oriri na-ezighi ezi ma ọ bụ oge nri): isi ọwụwa, agụụ siri ike, ọgbụgbọ, ọgbụgbọ, ike ọgwụgwụ, nsogbu ịrahụ ụra, mgbagha, mgbagha, iwe iwe, ịda mba ngwa ngwa, iwelata mmeghachi omume, ịda mba, enweghị enyemaka, ahụhụ na nsogbu okwu. , aphasia, paresis, ịma jijiji, mbelata uche, obi ọgbụgba, bradycardia, ụdara, ọnwụ nke njide onwe onye, ura, iku ume, enweghị nke nsụhọ, iche echiche, na - eduga n'ọma na ọnwụ. Ihe mgbaàmà adrenergic ga - ekwe omume: ọsụsọ nnyapade, ụjọ, tachycardia, ọbara mgbali elu, ihe mgbu n'obi, arrhythmia

mgbu afọ, ọgbụgbọ, vomiting, afọ ọsịsa, afọ ntachi (enwere ike belata site na ị theụ ọgwụ n'oge nri ụtụtụ)

mmụba mgbanwe enwere na ọkwa nke enzymes hepatic (ALT, AST, alkaline phosphatase), ịba ọcha n'anya (adịkarịghị), hyponatremia

ọnya ọnya, itching, urticaria, angioedema, erythema, maculopapular rashes, mmeghachi omume jọgburu (dịka ọrịa Stevens-Johnson syndrome, necrolysis na-egbu egbu)

anaemia, leukopenia, thrombocytopenia, granulocytopenia, pancytopenia (atụgharịghachi mgbe ịkwụsị ọgwụ)

ọhụhụ anya na - adị ala, ọkachasị na mmalite ọgwụgwọ, n'ihi mgbanwe nke ọbara ọgbụgba

Ihe ngbanwe

A maara hypersensitivity na gliclazide ma ọ bụ otu n'ime ihe inyeaka nke ọgwụ ahụ, yana ọgwụ ndị ọzọ nke ụdị sulfonylurea ma ọ bụ sulfonamides.

ụdị shuga 1

ọrịa mamịrị ketoacidosis, precomatosis na ọrịa shuga

nnukwu akụrụ ma ọ bụ imeju akwara

ime na lactation

Mkparịta ụka ọgwụ ọjọọ

Ejikọtara ojiji nke gliclazide na miconazole n'ihe metụtara ọghọm hypoglycemia, ruo hypoglycemic coma.

A akwadoghị Glyclazide maka iji ya eme ihe n'otu oge yana phenylbutazone na mmanya n'ihi oke ụba nke hypoglycemia. N’oge ịgwọ ọgwụ ahụ, ọ dị mkpa izere ị drinkingụ mmanya na ị medicationsụ ọgwụ nwere mmanya.

N'ihe banyere ihe ize ndụ nke ịmalite hypoglycemia, a ga-akpachara anya mgbe ị na-ede akwụkwọ ọgwụ gliclazide na antidiabetic nke otu ndị ọzọ (insulins, acarbose, biguanides), beta-blockers, fluconazole, angiotensin-na-agbanwe enhibido enzyme inhibitors (captopril, enalapril), na H2 receptor antagon (IMAO), sulfonamides na ọgwụ mgbochi mbufụt Steroid.

A naghị atụ aro iji ọdịnaya gliclazide na danazol n'ihi ihe mmụba nke glucose ọbara. Ọ bụrụ na ọ dị mkpa, nhọpụta nke njikọta dị otú a kwesịrị iji nlezianya nyochaa ọkwa nke glucose dị n'ọbara na mmamịrị, na n'ọnọdụ ụfọdụ, dozie ọnụọgụ nke gliclazide n'oge ọgwụgwọ na danazol na mgbe ọ gachara.

N'iburu n'uche ihe ize ndụ nke ịmalite hyperglycemia, akpachara anya kwesịrị ịkpachara anya mgbe ị na-ejikọta gliclazide na chlorpromazine (na ọnụọgụ nke> 100 mg kwa ụbọchị, nke ikpeazụ na-eme ka mbelata insulin). Maka oge ọgwụgwọ chlorpromazine, enwere ike ịchọ ndozi nke gliclazide.

Glucocorticosteroids (maka sistemu na nke mpaghara: intraarticular, sub- ma ọ bụ subcutaneous, rectal) na tetracosactides, mgbe ejikọtara ya na glycoslazide, na-abawanye ọkwa glucose ọbara na, n'ihi mbelata nke ịnabata carbohydrate, nwere ike ibute ketosis. N'oge ọgwụgwọ na mgbe ọgwụgwọ glucocorticoid gasịrị, enwere ike ịchọ nhazi nke gliclazide.

Ekwesịrị iji nlezianya mee ihe na ojiji gliclazide na ritodrine, salbutamol na tertbutaline (intravenously) n'ihi ihe egwu nke ịbawanye hyperglycemia. Ọ bụrụ na ọ dị mkpa, gaa na ọgwụ insulin.

Site na iji gliclazide jikọtara ọnụ na anticoagulants (warfarin, wdg), enwere ike ịhụbawanye mmetụta anticoagulant.

Ntụziaka pụrụ iche

Ekwesịrị ịnye ọgwụ ahụ naanị ka onye ọrịa nweta ya (yana nri ụtụtụ).

Ihe ize ndụ nke hypoglycemia na-abawanye site na nri nwere kalori, mgbe ọ gbasịrị ogologo oge ma ọ bụ mgbatị anụ ahụ, ị drinkingụ mmanya na-egbu egbu, ma ọ bụ n'ihe banyere ojiji nke ọtụtụ ọgwụ ọgwụ hypoglycemic.

N'iburu n'uche ịbawanye ụba nke hypoglycemia, a na-atụ aro ka ị takeụọ carbohydrates mgbe niile (ma ọ bụrụ na a na-eri nri mbubreyo, ma ọ bụrụ na nri ezughi oke, ma ọ bụ ma nri nwere obere carbohydrate).

Hypoglycemia nwere ike ịmalite mgbe ejirila ụdị sulfonylurea. Oge ụfọdụ nwere ike ịdị njọ ma ogologo oge. Enwere ike ịchọ ụlọ ọgwụ, glucose nwekwara ike ịchọ ọtụtụ ụbọchị.

Iji belata ihe egwu nke ịmalite hypoglycemic nke ọma, a chọrọ ntuziaka onye ọrịa.

Ihe na - eme ka ịbawanye hypoglycemia pụta:

Nnyefere

Mgbaaka na imeju imeju: Ngwá ọgwụ na ọgwụ ọgwụ nke gliclazide nwere ike ịgbanwe na ndị ọrịa nwere ọrịa ịba ọcha n'anya ma ọ bụ ọdịda siri ike. Ọnọdụ hypoglycemic nke na-eme n'ime ndị ọrịa dị otú a nwere ike ịnọ ogologo oge, ya mere a ga-eduzi nyocha kwesịrị ekwesị.

Ekwesịrị ịgwa onye ọrịa banyere mkpa iri nri, mkpa maka mmega ahụ oge niile na ilele ọkwa glucose ọbara. Ọrịa na ezinụlọ ha kwesịrị ịkọwa ihe egwu nke hypoglycemia, na-ekwu maka mgbaàmà ya, ụzọ ọgwụgwọ yana ihe ndị na-ebute mmepe nke nsogbu a.

Njikwa glucose ọbara dị ala

Ọ nwere ike imetụta ịdị mma nke ịchịkwa mkpokọta glucose n'ọbara nke onye ọrịa na-anata ọgwụgwọ antidiediiki site na ihe ndị a: ahụ ọkụ, ọnya ahụ, ọrịa, ma ọ bụ usoro ịwa ahụ. N'ọnọdụ ụfọdụ, ọ nwere ike ịdị mkpa ịkọ ọgwụ insulin.

Hydị adị hypoglycemic nke ọgwụ antidiabetic ọ bụla, gụnyere gliclazide, n'ọtụtụ ndị ọrịa na-ebelata ka oge na-aga n'ihi mmụba nke ọrịa shuga ma ọ bụ mbelata mmeghachi omume na ọgwụ (enweghị usoro ọgwụgwọ ọgwụgwọ nke abụọ). Nkwubi okwu banyere enweghị nke abụọ nke nsonaazụ ọgwụgwọ nwere ike ịme naanị mgbe ọ bụla ịmeghari ọgwụ zuru oke yana ọ bụrụ na onye ọrịa ahụ na-agbaso nri.

Mgbe ị na-atụle njikwa nke glucose ọbara, a na-atụ aro ka a tụọ ọ̀tụ̀tụ̀ hemoglobin glycated (ma ọ bụ glucose na plasma ọbara nke ọbara venous).

Cribdebere ọgwụ ọrịa sulfonylurea nye ndị ọrịa nwere ụkọ glucose-6-phosphate dehydrogenase nwere ike ibute anaemia haemolytic. Ekwesịrị ịkpachara anya mgbe ị na-edepụta gliclazide n'ime ndị ọrịa nwere ụkọ glucose-6-phosphate dehydrogenase ma na-atụle ọgwụgwọ ọzọ na ọgwụ nke klas ọzọ.

Ozi Pụrụ Iche na Ndị Ọpụrụiche

Gliclada® nwere lactose. Ndị ọrịa nwere ọrịa ụbụrụ nke galactose ekweghị ibe nọrọ, ụkọ Lappase ma ọ bụ ọrịa glucose-galactose ekwesịghị ịoseụ ọgwụ a.

Akụkụ nke nsonaazụ nke ọgwụ nwere ike ịkwọ ụgbọala ma ọ bụ usoro ndị nwere ike ịdị ize ndụ

Ekwesịrị ịkpachara anya mgbe ị na-anya ụgbọala ma ọ bụ usoro ndị ọzọ, karịsịa na mmalite ọgwụgwọ.

Dodoụbiga ya ókè

Ọrịa agafeghị oke na hypoglycemia.

Ọgwụgwọ: ihe mgbaàmà nke hypoglycemia dị ala na-enweghị ọnwụ nke mmụọ ma ọ bụ ihe ịrịba ama nke nsogbu akwara ozi, wepụ ihe oriri nke carbohydrates, mmezi dose na / ma ọ bụ mgbanwe nri. Ekwesịrị ịdị na-ahụ maka nlekọta ahụike ruo mgbe dọkịta jide n'aka na onye ọrịa ahụ kwụsiri ike ma ghara itinye nsogbu.

Ọnọdụ siri ike nke hypoglycemia, tinyere coma, nkwarụ ma ọ bụ nsogbu akwara ndị ọzọ, chọrọ nlekọta mberede na ụlọ ọgwụ ozugbo. Ọ bụrụ n ’hypoglycemic coma pụtara ma ọ bụ na-enyo enyo, glucagon na 50 ml nke glucose ọgwụ mejupụtara (20-30% intravenously) kwesịrị ịbanye ozugbo, wee gaa n’ihu ịgbanye glucose 10% na ọnụego nke na-ahụ na ọbara mgbanye ọbara karịrị 1 g / l. . Ọrịa kwesịrị ịnọ n'okpuru nlekọta ahụike siri ike. Usoro ọgwụgwọ adịghị irè.

Ndị na-ahụ maka ọgwụ

Ndị na-ahụ maka ọbara hypoglycemic, sulfonamides, ihe urea. Usoro ATX A10V B09.

Glyclazide bụ ọgwụ apoụara hypoglycemic ọgwụ, bụ ihe na-enye sulfonialurea, nke dị iche na ọgwụ ndị ọzọ site na ọnụnọ nke heterocyclic nwere nitrogen ma nwee agbụ endocyclic.

Gliclazide na-ebelata ọkwa glucose plasma n'ihi mkpali nke insulin na-egbochi site na mkpụrụ ndụ lets nke agwaetiti dị na Langerhans. Mmụba na ọkwa nke insprandial insulin na nzuzo nke C-peptide na-adịgide ọbụna mgbe afọ 2 nke iji ọgwụ ahụ gasịrị. Gliclazide nwekwara akwara haemovascular.

Mmetụta insulin insulin.

N'ime ndị ọrịa nwere ọrịa shuga nke II, gliclazide weghachi mmalite mbuzo nke insulin na nzaghachi glucose ma na-abawanye usoro nke abụọ nke insulin. Mmụba dị ukwuu na mmiri insulin na-eme dabere na nri nri ma ọ bụ ibu glucose.

Glyclazide na-ebelata microthrombosis n'ihi usoro abụọ nwere ike itinye aka na mmepe nke nsogbu nke ọrịa mellitus:

akụkụ ụfọdụ na-egbochi nchịkọta platelet na njikọta, na-ebelata ọnụ ọgụgụ ihe nrụpụta platelet (β-thromboglobulin, thromboxane B 2)
na-emetụta ọrụ fibrinolytic nke vaskụla endothelium (na-eme ka ọrụ tRA dịkwuo elu).

Isi ihe mejupụtara ya bụ isi akwara mkpụrụ obi (ọrịa obi, ọrịa infarction na-abụghị nke na-egbu egbu) na ọrịa microvascular (okwu ọhụụ ma ọ bụ na-akawanye njọ nephropathy, retinopathy).

11,140 ndị ọrịa gụnyere na nnwale ụlọ ọgwụ. N'ime izu isii nke mmalite, ndị ọrịa nọgidere na-a therapyụ ọgwụ shuga dị ala ha na-emebu. Mgbe ahụ, dị ka usoro enweghị usoro, e kenyere ndị ọrịa ọkọlọtọ nchịkwa nchịkwa (n = 5569) ma ọ bụ nchịkwa nchịkwa nke glycoslide, mbadamba ndị a na-ahapụ, dabere na usoro nke nchịkwa glycemia kpụ ọkụ n'ọnụ (n = 5571). Atụmatụ maka nchịkwa glycemic siri ike dabere na nhọpụta nke gliclazide, mbadamba nkume ndị nwere mgbanwe ewepụtara, site na mbido ọgwụgwọ, ma ọ bụ na mgbe a họpụtara gliclazide, mbadamba nkume nwere ntọhapụ agbanwere, kama usoro ọgwụgwọ (ọgwụgwọ ahụ onye ọrịa natara n'oge nsonye), na enwere ike ịbawanye uru na dose ruo n’ogologo na mgbe ahụ na mgbakwunye nke ọgwụ shuga ndị ọzọ dị ala, ọ bụrụ na ọ dị mkpa, dị ka metformin, acarbose, thiazolidinediones ma ọ bụ insulin. A na-enyocha ndị ọrịa anya ma na-agbasochi usoro nri.

Nyocha ahụ were afọ 4.8. Nsonaazụ nke ọgwụgwọ na gliclazide, mbadamba ihe eji agbanwe, nke bụ ntọala nke atụmatụ maka nchịkwa glycemic kpụ ọkụ n'ọnụ (nkezi enweta ogo HbAlc - 6.5%) ma e jiri ya tụnyere njikwa glycemia (nkezi enweta ogo HbAlc - 7.3%), enwere nnukwu mbelata nke mkpokọta. Ihe dị ka nsogbu 10% nke nnukwu nnukwu nsogbu na nsogbu microvascular ((HR) 0.90, 95% Cl 0.82, 0.98 p = 0.013, 18.1% nke ndị ọrịa sitere na otu nchịkwa kpụ ọkụ n'ọnụ ma e jiri ya tụnyere 20% nke ndị ọrịa site na otu ahụ akara ọkọlọtọ). Uru nke atụmatụ maka nchịkwa glycemic kpụ ọkụ n'ọnụ na nhọpụta nke gliclazide, mbadamba mbugharị ndị gbanwetụrụ na usoro ọgwụgwọ bụ n'ihi:

mbelata dị ukwuu n’ihe ọghọm nke ihe dị obere microvaskụla site na 14% (HR 0.86, 95% Cl 0.77, 0.97, p = 0.014, 9.4% dị ka 10.9%),
mbelata nke ukwuu n'ihe ọghọm nke ọhụụ ma ọ bụ mgbanwe nke nephropathy site 21% (HR 0.79, 95% Cl 0.66 - 0.93, p = 0.006, 4.1% na 5.2%),
mbelata nke 8% na ọghọm dị na microalbuminuria nke mere na nke mbụ (HR 0.92, 95% Cl 0.85 - 0.99, p = 0.030, 34.9% na 37.9%),
mbelata nke ukwuu n'ihe banyere ọghọm nke ihe na-eme site na 11% (HR 0.89, 95% Cl 0.83, 0.96, p = 0.001, 26.5% megide.

Na ngwụsị nke ọmụmụ ahụ, 65% na 81.1% nke ndị ọrịa nọ na njikwa ike (ihe dị ka 28.8% na 50.2% nke otu nchịkwa ọkọlọtọ) mezuru HbAlc ≤ 6.5% na ≤ 7%, n'otu n'otu. 90% nke ndị ọrịa nọ na ngalaba nchịkwa kpụ ọkụ n'ọnụ were gliclazide, mbadamba nkume nwere ntọhapụ gbanwee (nkezi kwa ụbọchị kwa ụbọchị bụ 103 mg), 70% n'ime ha were ọnụọgụ kwa ụbọchị nke 120 mg. N'ime ìgwè nchịkwa glycemic kpụ ọkụ n'ọnụ dabere na gliclazide, mbadamba mbugharị gbanwetụrụ, ịdị arọ nke onye ọrịa ahụ kwụsiri ike.

Uru nke usoro maka nchịkwa glycemic kpụ ọkụ n'ọnụ dabere na gliclazide, mbadamba ihe eji agbanwe, agbanwebeghị na wedata ọbara mgbali elu.

Ọkwa gliclazide na plasma ọbara na-ebili n'oge elekere isii nke mbụ, na-eru ala dị larịị bụ isii ruo awa iri na abụọ mgbe nchịkwa ọgwụ gasịrị.

Ikike iche-iche n'otu n'otu enweghị elele.

Glyclazide na-etinye obi gị dum. Iri nri anaghị emetụta ọnụego ya na oke nnabata.

Njikọ protein protein Plasma bụ ihe dịka 95%. Mmekọrịta dị n'etiti ọgwụ a na-agbago ruo 120 mg na mpaghara dị n'okpuru usoro ịta ahụhụ bụ ahịrị. Olu nkesa kesara odi lita 30.

Gliclazide bụ metabolized na imeju ma mpụta ya na mmamịrị; ihe na-erughị 1% nke ihe na-arụ ọrụ na-apụtakarị na mmamịrị agbanwe agbanwe. Ọ dịghị metabolites nọ n'ọrụ na plasma.

Ọkara ọkara nke gliclazide bụ awa 12-20.

N'ime ndị ọrịa agadi, enweghi mgbanwe mgbanwe dị ukwuu na ụlọ ọgwụ ọgwụ ọgwụ.

Otu ọgwụ Glyclada nke otu ọgwụ, mbadamba nkume ndị nwere ndọtị na-agbanwe agbanwe, na-ekwusi ike na glycazide na plasma ruo awa 24.

IIdị nke ọrịa shuga nke II:

mbelata na ịchịkwa glucose ọbara ma ọ bụrụ na ọ gaghị ekwe omume ịhazi ọkwa glucose naanị site na nri, mmega ahụ ma ọ bụ belata
igbochi nsogbu nke ọrịa shuga II nke ọrịa mellitus: na -ebelata ihe ize ndụ nke nnukwu nsogbu na microvascular, gụnyere ọrịa ọhụụ ma ọ bụ na-akawanye njọ na ndị ọrịa nwere ụdị ọrịa shuga mellitus II.

Emeputa

Krka, dd Novo Mesto, Slovenia

Marješka 6, 8501 Novo Mesto, Slovenia

Adreesị nke nzukọ ahụ na-anabata ihe ndị na-azụ ahịa na-ekwu maka ịdị mma nke ngwaahịa (ngwongwo) na Republic of Kazakhstan

Krka Kazakhstan LLP, Kazakhstan, 050059, Almaty, Al-Farabi Ave. 19, ụlọ 1 b,

Mmekọrịta na ọgwụ ndị ọzọ na ụdị mmekọrịta ndị ọzọ

Mgbe ị na-eji ọgwụ ọjọọ eme ihe, nhazi nke oge nke nwere ike ibute hypoglycemia, Sidid dọrọ onye ọrịa ahụ mkpa ọ dị iji nlezianya na-elebara ọkwa glucose ọbara n'oge ọgwụgwọ. Enwere ike ịchọ ndozi nke ọgwụ hypoglycemic n'oge ọgwụgwọ na ọgwụ ndị a.

Ogwu nwere ike ịbawanye ohere nke hypoglycemia

Miconazole (maka sistem, oromucous gel) na-eme ka mmetụta hypoglycemic dị elu site na mmepe nke mgbaàmà hypoglycemia ma ọ bụ ọbụna coma.

Ngwakọta agwaghị ya

Phenylbutazone (maka iji usoro) mee ka mmetụta hypoglycemic nke sulfonylurea (dochie njikọ ya na protein plasma na / ma ọ bụ belata ihe ọ rụpụtara). Ọ bụ ihe amamihe dị na ya iji ọgwụ mgbochi ọzọ na-adọta uche onye ọrịa na mkpa ọ dị ijide onwe ya. Ọ bụrụ na ọ dị mkpa, a na-achịkwa usoro onunu ogwu nke Glyclad n'oge ọgwụgwọ ọgwụ mgbochi mkpali.

Mmanya na-eme ka mmeghachi omume hypoglycemic dị mma (site na igbochi mmeghachi ụgwọ nkwụghachi ụgwọ), nke nwere ike ibute mmalite nke hypoglycemic coma. Zere iji ọgwụ ndị nwere mmanya na-aba n'anya, yana ị .ụ mmanya.

Mgwakọta chọrọ ịkpachara anya

Ngkwalite mmetụta hypoglycemic nke ọgwụ ahụ na, n'ọnọdụ ụfọdụ, hypoglycemia nwere ike ịmalite n'ihi ojiji nke ọgwụ antidiabetic ndị ọzọ na ọgwụ ndị dị ka insulin, acarbose, metformin, thiazolidinediones, dipeptidyl peptidase 4 inhibitors, glucose-1-phosphate receptor, beta, ACE inhibitors (captopril, enalapril), ndị antagonist H 2 na-anabata ihe, MAO inhibitors, sulfonamides, clarithromycin, na ọgwụ mgbochi mgbochi steroidal.

Ọgwụ ndị nwere ike ime ka mmụba glucose ọbara

Ngwakọta agwaghị ya

Danazole: Mmetụta diabetogenic nke Danazol.

Ọ bụrụ na-enweghị ike igbochi ojiji nke ihe a na-arụ ọrụ, a ga-adọ onye ọrịa aka na ntị banyere mkpa ọ dị ịdị na-enyocha glucose na mmamịrị na ọbara. Ọ nwere ike ịdị mkpa ịhazigharị usoro ọgwụ ndị na - egbu ọgwụ mgbu n'oge ọgwụgwọ na danazol.

Mgwakọta chọrọ ịkpachara anya

Chlorpromazine (antipsychotic): iji ọgwụ chlorpromazine dị elu (> 100 mg kwa ụbọchị) na-abawanye ọkwa glucose na ọbara (n'ihi mbelata insulin insulin).

E kwesịrị ịdọ onye ọrịa ọdụ banyere mkpa ọ dị ịdị na-enyocha ọkwa glucose ọbara. Ọ nwere ike ịdị mkpa ịhazigharị usoro ọgwụ antidiabetic na-arụ ọrụ n'oge yana mgbe ọgwụgwọ antipsychotics gasịrị.

Glucocorticoids (maka usoro na ọgwụ eji eme ihe: intraarticular, akpụkpọ ahụ na nhazi akụkụ) na tetracosactrin na-abawanye glucose ọbara na mmepe nke ketosis (n'ihi nkwụsị nke carbohydrates site na glucocorticoids).

E kwesịrị ịdọ onye ọrịa ọdụ banyere ịdị mkpa na ịdị mkpa nke nyochaa ọkwa glucose ọbara, karịsịa na mmalite ọgwụgwọ. Ọ nwere ike ịdị mkpa ịhazigharị ọgwụ nke ọgwụ ndị na-egbu egbu n'oge ọgwụgwọ glucocorticoid na mgbe ọ gachara.

Ritodrin, salbutamol, terbutaline (c) na-abawanye ọkwa glucose na ọbara n'ihi ihe agonist beta-2.

Ekwesiri ịdọ aka ná ntị banyere mkpa ọ dị ịchịkwa ọkwa glucose ọbara. Ọ bụrụ na ọ dị mkpa, a ga-ebufere onye ọrịa ahụ insulin.

Njikọ ọnụ iji lelee anya

Ọgwụ na anticoagulants (dị ka warfarin, wdg) Nkwado sulfonylurea nwere ike ịkwalite mmetụta anticoagulant na ọgwụgwọ concomitant. Enwere ike ịchọ ndozi ọgwụ Anticoagulant.

Njirimara ngwa

Edere usoro ọgwụgwọ nye ndị ọrịa nwee ike ịgbaso nri zuru oke na mgbe niile (gụnyere nri ụtụtụ). Ọ dị mkpa ị na-a carbohydụ carbohydrates oge niile n'ihi oke ụba nke hypoglycemia, nke na-apụta mgbe a na-egbu nri n'oge, na-ezughị ezu, ma ọ bụ ma ọ bụrụ na nri dị na carbohydrates dị ala. Ihe ize ndụ nke hypoglycemia na-abawanye site na obere kalori na-eri nri, ogologo oge ma na-emega ahụ siri ike, yana mmanya ma ọ bụ na ijikọ ndị nnọchi hypoglycemic.

Hypoglycemia nwere ike ime n'ihi otu oge eji eme ihe maka usoro sulfonylurea na (lee “Mmeghachi omume”) n'ụfọdụ ihe nwere ike ịbụ nke siri ike ma dị ogologo. Mgbe ụfọdụ, a chọrọ ịga ụlọ ọgwụ na ojiji nke glucose ruo ọtụtụ ụbọchị.

Nnyocha zuru ezu nke ndị ọrịa, iji otu ọgwụ ụfọdụ yana ịgbaso usoro onunu ogwu na ntinye akwụkwọ dị mkpa iji belata ihe ize ndụ hypoglycemia.

Ihe na - eme ka ịbawanye hypoglycemia pụta:

ọjụjụ ma ọ bụ (karịchaa ndị agadi agadi) enweghị ike imekọrịta ihe,
obere kalori ma ọ bụ nri n’oge, nri dịịrị ọnụ, oge ibu ọnụ ma ọ bụ mgbanwe nri,
imebi nguzozi di n'etiti aru oru ahu na aru ndi mmadu ,uru ndi ahuru na ahihia.
gbasara akwara
nnukwu ikeji imeju
ngafe nke Glyclad,
ọrịa ụfọdụ nke usoro endocrine: ọrịa thyroid, hypopituitarism na adrenal insufficiency,
n'otu oge iji ụfọdụ ọgwụ ndị ọzọ (lee mpaghara “ractionmekọrịta ọgwụ ndị ọzọ na ụdị mmekọrịta ndị ọzọ”).

Mgbaaka na imeju imeju

Pharmacokinetics na / ma ọ bụ pharmacodynamics nke gliclazide nwere ike ịdị iche na ndị ọrịa nwere ọrịa ịba ọcha n'anya ma ọ bụ ọdịda siri ike. Ọnọdụ nke hypoglycemia nke na-eme ndị ọrịa dị otú ahụ nwere ike ịgbatị ma chọọ usoro ụfọdụ.

Ozi Ndidi

A ga-adọ onye ọrịa ahụ na ndị ezinụlọ ya aka na ntị banyere ihe ize ndụ nke hypoglycemia, kọwaa ihe mgbaàmà ya (lee akụkụ "Mmeghachi omume"), ọgwụgwọ, yana ihe ndị na-abawanye n'ihe ize ndụ nke mmepe ya.

Ndị ọrịa kwesịrị ịma mkpa nri, mmega ahụ oge niile, na ịtụle glucose ọbara n'ọbara.

Imebi iwu nke glucose ọbara

Ihe ndị a nwere ike imetụta nhazi nke ọkwa glucose ọbara na ndị ọrịa na-a drugsụ ọgwụ antidiedi: ahụ ọkụ, trauma, ọrịa, ma ọ bụ ịwa ahụ. N'ọnọdụ ụfọdụ, enwere ike ịchọ insulin.

Ọrịa hypoglycemic dị mma nke ọgwụ antidiabetic ọ bụla, gụnyere gliclazide, na-ebelata ka oge na-aga n'ọtụtụ ndị ọrịa: nke a nwere ike ime n'ihi mmụba nke ọrịa shuga ma ọ bụ mbelata mmeghachi omume na ọgwụgwọ. A maara nke a dị ka ọdịda nke abụọ, nke dị iche na nke mbụ mgbe ihe ahụ na-arụ ọrụ adịghị arụ ọrụ na iji ọgwụ mbụ. Ekwesịrị imeghari usoro kwesịrị ekwesị na nri tupu ịmee ka onye ọrịa banye na ngalaba ọdịda nke abụọ.

A na-atụ aro ka ị chọpụta ọkwa nke haemoglobin glycosylated (ma ọ bụ ọkwa shuga na plasma ọbara venous). Inwe nnyocha banyere glucose ọbara nwekwara ike ịbụ ihe kwesịrị ekwesị.

Treatmentgwọ ndị ọrịa nwere ụkọ glucose-6-phosphate dehydrogenase na nkwanye sulfonylurea nwere ike ibute anaemia haemolytic. Ebe ọ bụ na gliclazide bụ nke kemịkal nke usoro nke sulfonylurea, ndị ọrịa nwere ụkọ glucose-6-phosphate dehydrogenase kwesịrị ịkpachara anya; a ga-atụlekwa ọgwụgwọ ọzọ na ọgwụ ndị na-enweghị sulfonylurea.

Ndụmọdụ Pụrụ Iche Banyere Isi Okwu

Gliclada nwere lactose. Ndị ọrịa nwere ọrịa lactose na-adịghị ahụkebe, na-enwe ụyọkọ galactosemia ma ọ bụ ọrịa glucose-galactose malabsorption ekwesịghị ị thisụ ọgwụ a.

Jiri n’oge ime ma ọ bụ n’ịra.

Enweghị ahụmịhe banyere ojiji nke gliclazide n'oge ime, ọ bụ ezie na enwere ụfọdụ ihe akaebe banyere ojiji nke sulfonylureas ndị ọzọ.

Ekwesịrị ịchịkwa ọrịa shuga tupu ịtụrụ ime iji belata ihe ize ndụ nke mmerụ ọrịa metụtara afọ iri nke na-enweghị enweghị nchịkwa ọrịa shuga.

A naghị atụ aro iji ọgwụ mgbochi antidiabet, insulin bụ ọgwụ kachasị maka ọgwụgwọ nke ọrịa shuga n'oge ime. A na-atụ aro ịnye onye ọrịa ahụ insulin ma ọ bụrụ na ime tụrụ ime ya ma ọ bụ mgbe ọ ga-eme.

Achọpụtaghị data banyere ntụtụ nke gliclazide ma ọ bụ metabolites ya n’ime mmiri ara. N’inye ya ohere ibute ọrịa hypoglycemia n’ime nwatakịrị, ọgwụ a machibidoro ị womenụ ụmụ nwanyị ara.

Ikike ime ka ọnụego mmeghachi omume dị mgbe ị na-anya ụgbọala ma ọ bụ na-arụ ọrụ na usoro ndị ọzọ.

Gliclada enweghị mmetụta a maara na ike ịkwọ ụgbọala ma ọ bụ jiri igwe rụọ ọrụ. Agbanyeghị, ndị ọrịa kwesịrị ịkpachara anya maka mmalite nke mgbaàmà hypoglycemia ma kpachara anya mgbe ha na-anya ụgbọala ma ọ bụ na-eji igwe, karịsịa mmalite ọgwụgwọ.

Mmeghachi omume ọjọọ

Dabere na ahụmịhe nke usoro gliclazide na sulfonylurea, a kọọrọ mmetụta ndị na-esote ya.

Ihe oriri na-adịghị adị oge ụfọdụ, yana obere nri mgbe a na-agwọ ọrịa nke nwere usoro sulfonylurea, gụnyere Glyclad, nwere ike ibute mmepe nke hypoglycemia. Ihe mgbaàmà puru iche nke hypoglycemia: isi ọwụwa, agụụ siri ike, ọgbụgbọ, ọgbụgbọ, ike ọgwụgwụ, nsogbu ịrahụ ụra, nchekasị, mgbakasị ahụ, ịta ụta, mpụ nke mmụọ na ibelata mmeghachi omume, ịda mba, ọhụhụ anya na okwu, aphasia, ịma jijiji, paresis, imetụ mmetụta. , ọgbụgba, ọnwụ nke njide onwe onye, iche echiche, ihe ịma jijiji, iku ume, bradycardia, iro ụra, ọnwụ nke mmụọ, yana nsonazụ nke mmụọ.

Na mgbakwunye, enwere ike igosipụta nsogbu nke usoro adrenergic: ọsụsọ excessiveụbiga ókè, arapara n'ahụ, nchekasị, tachycardia, ọbara mgbali elu, nkwonkwo obi, angina pectoris na arrhythmia.

Ihe mgbaàmà na-apụ n'anya mgbe ị carbohydụsịrị carbohydrates (sugar). Agbanyeghị, ndị na-atọ ụtọ mmụọ anaghị enwe mmetụta. Ahụmahụ ahụ nwere nkwadebe ndị ọzọ na-egosi na hypoglycemia nwere ike ime ugboro ugboro, ọ bụrụgodi na e weere usoro dị mma ozugbo.

Ọ bụrụ na ọrịa hypoglycemia siri ike ma na-adịte aka, ọbụlagodi ma ọ bụrụ na shuga na-achịkwa ya ruo nwa oge, ịga ụlọ ọgwụ ozugbo na nlekọta ahụike mberede dị mkpa.

A na-achọpụta ọtụtụ ọrịa hypoglycemia na ndị ọrịa nwere ọgwụ insulin na-emegharị ahụ.

Nsonaazụ ndị ọzọ

Site na eriri afọ: mgbu afọ, ọgbụgbọ, ọgbụgbọ, dyspepsia, afọ ọsịsa na afọ ntachi. Enwere ike iwepu ma ọ bụ belata mgbaàmà ndị a site na ị gụ gliclazide n'oge nri ụtụtụ.

Ihe ndị a bụ mmetụta ndị achọghị.

N’akụkụ anụ ahụ na ọnya subcutaneous: ihe ọkụ ọkụ, itching, urticaria, angioedema, redness, ọrịa akwarapapular, mmeghachi omume obi (dịka ọmụmaatụ Stevens-Johnson syndrome na necrolysis na-egbu egbu).

Site na sistemụ ngagharị na lymphatic: mgbanwe na mgbochi hematological, gụnyere anaemia, leukopenia, thrombocytopenia, granulocytopenia. Ihe omume ndị a dị ụkọ ma na - apụkarị n'anya mgbe ị kwụsịrị ọgwụ.

N'akụkụ nke imeju na ọnya biliary: mmụba nke ọkwa enzymes imeju (AST, ALAT, alkaline phosphatase), ịba ọcha n'anya (ikpe ndị dịpụrụ adịpụ). N'ihe banyere cholestatic jaundice, ekwesịrị ịkwụsị ọgwụ nke ọgwụ.

Site n'akụkụ akụkụ ahụ nke ọhụụ: nkwarụ anya nke nwa oge, n'ihi mgbanwe nke ogo glucose n'ọbara, nkwarụ anya nwa oge na-apụta, ọkachasị na mmalite ọgwụgwọ.

Mmetụta pụta ụwa na ngwaahịa sulfonylurea:

Dị ka ọ dị na ndokwa ndị ọzọ e mere maka erythrocytopenia, agranulocytosis, hemolytic anaemia, pancytopenia, vasculitis nfụkasị, hyponatremia, enzymes imeju na-arụ ọrụ na-arụ ọrụ (dịka ọmụmaatụ, ya na cholestasis na jaundice) na ịba ọcha n'anya na-apụ mgbe ịkwụsịchara ma ọ bụ mẹ nwoke ọzo ikpe dobewaru ndu ojọgu.

Ngwongwo ogwu

Gliclazide na -ebelata ọkwa glucose plasma n'ihi mkpali nke insulin na-egbochi site na mkpụrụ ndụ β-sel nke mpaghara ntụpọ nke Langerhans. Mmụba na ọkwa nke insprandial insulin na nzuzo nke C-peptide na-adịgide ọbụna mgbe afọ 2 nke iji ọgwụ ahụ gasịrị.

Gliclazide nwekwara akwara haemovascular.

Mmetụta insulin insulin.

Gliclazide belata microthrombosis site na usoro abụọ nwere ike itinye aka na mmepe nke nsogbu nke ọrịa mellitus:

akụkụ ụfọdụ na-egbochi nchịkọta platelet na njikọta, na-ebelata ọnụ ọgụgụ ihe nrụpụta platelet (β-thromboglobulin, thromboxane B 2)
na-emetụta ọrụ fibrinolytic nke vaskụla endothelium (na-eme ka ọrụ tRA dịkwuo elu).

Mgbochi nsogbu nke ụdị shuga II.

ADVANCE bu ihe eji eme ikpere mba na mba di iche-iche na ihe eji eme otutu ihe, nke achoputara abamuru nke njikwa glycemic control (HbAlc ≤ 6.5%) dabere na mbadamba ihe mwepu nke glycoslide (Gliclazide MR) dika atule glycemic control na uru nke iwetulata obara mgbali. nrụgide site na iji nchikota nke perindopril / ebepamide ma e jiri ya tụnyere placebo na ndabere nke usoro ọgwụgwọ ugbu a (ntụnyere anya abụọ) dị ka mmetụta dị na isi micro- na microvascular ihe omume na ndị ọrịa nwere ụdị II ọrịa shuga.

Ọmụmụ ihe ahụ gụnyere ndị ọrịa 11 140 nwere ụdị ọrịa shuga mellitus nke II (pụtara: afọ 66 afọ, BMI (body mass index) 28 kg / m 2, oge afọ nke ọrịa shuga afọ 8, ọkwa HbAlc nke 7.5% na SBP / DBP (systolic systolic) ọbara mgbali ọbara / diastolic ọbara) 145/81 mmHg). N'ime ndị ọrịa a, 83% nwere ọbara mgbali elu, na ndị ọrịa 325 na na 10%, edere ọrịa macro-na micro-vaskụla n'akụkọ ihe mere eme nke ọrịa ahụ, n'otu n'otu, na 27%, achọpụtara microalbuminuria (MAU). A na-agwọ ọtụtụ ndị ọrịa tupu ọrịa shuga II, 90% - site na ị theụ ọgwụ (47% - monotherapy, 46% - ọgwụgwọ abụọ na 7% - triple therapy) na 1% nwere insulin ebe 9% nọ naanị na nri. Na mbu, sulfonylurea (72%) na metformin (61%) ka enyere n'iwu. Usoro ọgwụgwọ concoitant gụnyere 75% nke ọgwụ na-ebelata ọbara mgbali elu (BP), ọgwụ na-egbusi ike (35%, tumadi statins - 28%), aspirin na ndị ọzọ na-ahụ maka antiplatelet (47%). N'ime oge izu isii nke nchịkwa nke njikọta nke perindopril / ebepamide na usoro ịbelata shuga, a na-ekenye ndị ọrịa ụkpụrụ nchịkwa nchịkwa glycemic (n = 5569), ma ọ bụ usoro MR glycazide dabere na atụmatụ nke nchịkwa glycemia siri ike (n = 5571). Atụmatụ maka njikwa glycemic siri ike dabere na ịkọwapụta Gliclazide MR site na nmalite ọgwụgwọ ma ọ bụ ịkọwa Gliclazide MR kama usoro ọgwụgwọ (ọgwụgwọ ahụ onye ọrịa ahụ na-enweta n'oge ntinye) na mmụba na-abawanye uru na nke kachasị ma mgbe ahụ, ọ bụrụ na ọ dị mkpa, mgbakwunye nke ọgwụ ndị ọzọ na-ebelata shuga, dị ka: metformin, acarbose, thiazolidinediones ma ọ bụ insulin. A na-enyocha ndị ọrịa anya ma na-agbasochi usoro nri.

Nyocha ahụ were afọ 4.8. Nsonaazụ nke ọgwụgwọ Gliclazide MR, nke bụ ntọala nke atụmatụ maka nchịkwa glycemic kpụ ọkụ n'ọnụ (nkezi enweta ogo HbAlc bụ 6.5%) ma e jiri ya tụnyere njikwa glycemia ọkọlọtọ (nkezi enweta ogo HbAlc bụ 7.3%), ọnụ ọgụgụ dị elu nke mbelata 10% na-akwụ ụgwọ ihe egwu nke nnukwu ihe ojoo na nsogbu microvascular ((HR) 0.90, 95% Cl 0.82, 0.98 p = 0.013, 18.1% nke ndị ọrịa sitere na otu nchịkwa kpụ ọkụ n'ọnụ ma e jiri ya tụnyere 20% nke ndị ọrịa si na otu nchịkwa ọkọlọtọ). Uru nke atụmatụ maka nchịkwa glycemic kpụ ọkụ n'ọnụ na nhọpụta MR gliclazide na ntọala nke ọgwụgwọ bụ n'ihi:

mbelata dị ukwuu n’ihe ọghọm nke isi ihe microvascular ihe site na 14% (HR 0.86, 95% Cl 0.77, 0.97, p = 0.014, 9.4% vs. 10.9%),
mbelata dị ukwuu n'ihe ọghọm nke ọhụụ ma ọ bụ mbido nephropathy site 21% (HR 0.79, 95% Cl 0.66 - 0.93, p = 0.006, 4.1% vs. 5.2%),
mbelata dị ukwuu n'ihe ọghọm microalbuminuria, nke bilitere na nke mbụ, site na 8% (HR 0.92, 95% Cl 0.85 - 0.99, p = 0.030, 34.9% vs. 37.9%),
mbelata nke ukwuu n'ihe banyere ọghọm nke ihe na-eme site na 11% (HR 0.89, 95% Cl 0.83, 0.96, p = 0.001, 26.5% vs. 29.4%).

Na ngwụsị nke ọmụmụ ahụ, 65% na 81.1% nke ndị ọrịa nọ na njikwa ike (vs 28.8% na 50.2% nke ọkọlọtọ njikwa ọkọlọtọ) mezuru HbAlc ≤ 6.5% na ≤ 7%, n'otu n'otu.

90% nke ndị ọrịa nọ na ngalaba nchịkwa kpụ ọkụ n'ọnụ were Gliclazide MR (nkezi kwa ụbọchị bụ 103 mg), 70% n'ime ha were ọnụọgụ kwa ụbọchị nke 120 mg. N'ime ìgwè nchịkwa glycemic kpụ ọkụ n'ọnụ nke dabeere na Gliclazide MR, ịdị arọ ahụ onye ọrịa ahụ kwụsiri ike.

Abamuru nke atụmatụ nchịkwa glycemic Glyce based Glycoslazide adabereghị na wedata ọbara mgbali elu.

Ọkwa gliclazide na plasma ọbara na-ebili n'oge 6:00 mbụ, na-eru ala dị larịị nke dịgidere ruo awa 6-12 mgbe nchịkwa ọgwụ ahụ gasịrị. Gliclazide na-etinye obi gị dum na eriri afọ. Iri nri anaghị emetụta ọnụego ya na oke nnabata.

Mmekọrịta dị n'etiti dose ahụ ruo 120 mg na mpaghara dị n'okpuru usoro ịta ahụhụ bụ ahịrị. Indmịnye protein ndị dị na plasma bụ 95%.

Gliclazide fọrọ nke nta ka ọ bụrụ metabolized n'ime imeju ma mpụta ya na mmamịrị. Ihe na-erughị 1% nke gliclazide bụ apụtaghị na mmamịrị. Ọ dịghị metabolites nọ n'ọrụ na plasma.

Ọkara ndụ nke gliclazide site na ahụ bụ awa iri na abụọ ruo iri abụọ na abụọ. Olu nkesa kesara odi lita 30.

Mgbe ị na-a aụ otu ọgwụ nke ọgwụ ahụ, a na-ahụ maka ịbanye nke gliclazide na plasma ọbara ruo awa 24.

N’ime ndị ọrịa agadi, anaghị agbanwe ọgwụ ndị na-ere ọgwụ.

Ọdịiche nke intra-onye dị ala.

IIdị nke ọrịa shuga nke II:

ibelata na ịchịkwa glucose ọbara mgbe ọ gaghị ekwe omume ịmeju ọkwa glucose naanị site na nri, mmega ahụ ma ọ bụ belata
igbochi nsogbu nke ọrịa shuga II nke ọrịa mellitus: na -ebelata ihe ize ndụ nke nnukwu nsogbu na microvascular, gụnyere ọrịa ọhụụ ma ọ bụ na-akawanye njọ na ndị ọrịa nwere ụdị ọrịa shuga mellitus II.

UmuakaChildren

Jiri n’oge ime ma ọ bụ n’ịra

A naghị atụ aro iji ọgwụ mgbochi antidiedi oral, insulin bụ ọgwụ kachasị maka ọgwụgwọ nke ọrịa shuga n'oge ime. A na-atụ aro ka onye ọrịa ahụ nyefee na insulin ma ọ bụrụ na ime tụrụ ime ma ọ bụ mgbe ọ mere.

Achọpụtaghị data banyere ntụtụ nke gliclazide ma ọ bụ metabolites ya n’ime mmiri ara. N’inye ihe ize ndụ nke ịmalite ịrịa hypoglycemia n’ime nwatakịrị, a ga-akwụsị ị useụ ọgwụ ahụ n’oge a na-enye nwa ara.